Feasibility is demonstrated in mammalian models for a therapeutic strategy that increases MBNL by sequestering MBNL-suppressive miRs.
The Myotonic Dystrophy Foundation honored both Senator Dick Durbin and Senator Diane Feinstein with MDF Congressional Leadership Awards for their outstanding work and support in getting myotonic dystrophy added as an eligible research area in the U.S. Department of Defense (DOD) Peer-Reviewed Medical Research Program (PRMRP) for Fiscal Year 2018 (FY18).
Insights on the mechanisms that underlie muscle atrophy in DM are provided by studies in a new mouse model.
The RNA binding protein, rbFOX1, competes with MBNL in binding to CCUGexp, but not CUGexp repeats, and thereby mitigates DM2.
The review journal, Frontiers in Neurology, is publishing six new articles on myotonic dystrophy.